Cisplatin and Continuous Infusion Fluorouracil (CF) for Head and Neck Cancers-Reference-Cited by-同舟云学术

Cisplatin and Continuous Infusion Fluorouracil (CF) for Head and Neck Cancers

Published:2005-09 Issue:9 Volume:40 Page:761-772
ISSN:0018-5787
Container-title:Hospital Pharmacy
language:en
Short-container-title:Hosp Pharm

Author:

Kem Ravie¹,Solimando Dominic A.²,Waddell J. Aubrey³

Affiliation:

1. Pharmaceutical Management Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, Maryland.

2. Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203

3. Oncology Pharmacy Residency Program, Department of Pharmacy, Walter Reed Army Medical Center, 6900 Georgia Avenue NW, Rm 2P02, Washington, DC 20307;

Abstract

The increasing complexity of cancer chemotherapy heightens the requirement that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy. It will also serve as a review of various agents, both commercially available and investigational, used to treat malignant diseases.

Publisher

SAGE Publications

Subject

Pharmacology (medical),Pharmacology,Pharmacy

Link

http://journals.sagepub.com/doi/pdf/10.1177/001857870504000905

Reference58 articles.

1. Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck

2. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin

3. Cisplatin and 5-fluorouracil chemotherapy in advanced or recurrent squamous cell carcinoma of the head and neck

4. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.